Skillnader

Här visas skillnader mellan den valda versionen och den nuvarande versionen av sidan.

--- leversteatos [2026/01/13 09:23] – akestorck
+++ leversteatos [2026/01/13 09:28] (aktuell) – akestorck
@@ Rad 16: / Rad 16: @@
 ==== Ultrasonography ====
-  * **Hyperechoic liver parenchyma** ("bright liver") compared to kidney or spleen ((1))
+  * **Hyperechoic liver parenchyma** ("bright liver") compared to kidney or spleen
   * **Grading**:
@@ Rad 22: / Rad 22: @@
 | Mild      | Slight echogenicity increase                   |
 | Moderate  | Impaired vessel wall visualization             |
-| Severe    | Poor diaphragm/portal vein visibility          |((2))
+| Severe    | Poor diaphragm/portal vein visibility          |
 ==== Computed tomography ====
-  * **Unenhanced CT**: Liver attenuation <40 HU absolute or >10 HU lower than spleen ((3))
+  * **Unenhanced CT**: Liver attenuation <40 HU absolute or >10 HU lower than spleen
-  * **Contrast-enhanced**: Focal sparing appears hyperdense relative to steatotic parenchyma (gallbladder fossa, segment IV) ((3))
+  * **Contrast-enhanced**: Focal sparing appears hyperdense relative to steatotic parenchyma (gallbladder fossa, segment IV)
-  * Dual-energy CT improves quantification ((4))
+  * Dual-energy CT improves quantification
 ==== Magnetic resonance imaging ====
-  * **Chemical shift imaging** (in/out-of-phase): Signal dropout on opposed-phase images (>5% fat) ((4))
+  * **Chemical shift imaging** (in/out-of-phase): Signal dropout on opposed-phase images (>5% fat)
-  * **Proton density fat fraction (PDFF)**: Gold standard for quantification ((4))
+  * **Proton density fat fraction (PDFF)**: Gold standard for quantification
   * **Spectroscopy**: Measures fat fraction directly
 ===== Treatment and prognosis =====
-Management targets underlying causes (weight loss, diabetes control). Steatosis alone carries excellent prognosis without fibrosis; NASH risks progression to cirrhosis (20-30%) ((5)).
+Management targets underlying causes (weight loss, diabetes control). Steatosis alone carries excellent prognosis without fibrosis; NASH risks progression to cirrhosis (20-30%).
 ===== Differential diagnosis =====
-  * Glycogen storage disease (US: hyperechoic but vessels clear) ((1))
+  * Glycogen storage disease (US: hyperechoic but vessels clear)
-  * Acute hepatitis (diffuse hypoechoic) ((6))
+  * Acute hepatitis (diffuse hypoechoic)
-  * Focal fat sparing/deposition mimics mass ((1))
+  * Focal fat sparing/deposition mimics mass
-  * Iron overload (high attenuation on CT) ((3))
+  * Iron overload (high attenuation on CT)
 ===== References =====
-* ((1)) [[https://pubs.rsna.org/doi/full/10.1148/rg.266065004|RadioGraphics 2006: Fatty Liver]]
+* [[https://pubs.rsna.org/doi/full/10.1148/rg.266065004|RadioGraphics 2006: Fatty Liver]]
-* ((2)) [[https://pmc.ncbi.nlm.nih.gov/articles/PMC6824276/|Ultrasound Med 20
+* [[https://pmc.ncbi.nlm.nih.gov/articles/PMC6824276/|Ultrasound Med 2019]]
+* [[https://ajronline.org/doi/10.2214/AJR.11.7838|AJR Am J Roentgenol 2012]]
+* [[https://pubs.rsna.org/doi/full/10.1148/radiol.2021204288|Radiology 2021]]
+* [[https://pmc.ncbi.nlm.nih.gov/articles/PMC4064084/|World J Gastroenterol 2014]]
+* [[https://www.sciencedirect.com/science/article/abs/pii/S0720048X06004451|Eur J Radiol 2007]]
+> **Medical Disclaimer**: Portions of this content were AI-generated to facilitate rapid knowledge synthesis. Radiologists and clinicians must independently verify all information against peer-reviewed literature, institutional protocols, and patient-specific factors before clinical application.